Discovery and development of fully human monoclonal antibody drugs
Kymab has developed a proprietary mouse platform that contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
-
Domain
-
Investment typeDirect equity
-
StatusExit
-
Initial investmentSeries C
-
Partnered in2014
-
Investment leadDavid Rossow
-
HeadquartersUnited Kingdom
-
Program strategyDiscovery & Translational Sciences
Portfolio news
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.